Novartis to Spend $70 Million More on R&D Each Month for Avidity
Novartis AG will spend as much as $70 million each month on research and development to advance Avidity…
UBS’ Senior Indonesia Wealth Banker Leaves Amid Several Exits
UBS Group AG’s senior wealth banker Lionel Yoong has left the Swiss firm, adding to several recent departures…
Roche Obesity Shot Led to 18% Weight Loss in Study
Roche Holding AG said patients on its experimental shot lost 18% more weight than those who got placebo…
Roche and Zealand Report 10.7% Weight Loss With Experimental Obesity Drug
An experimental obesity shot from Roche Holding AG and Zealand Pharma A/S failed to meet industry expectations in…
Roche MS Pill Cuts Relapses But Safety Questions Persist
Roche Holding AG’s experimental multiple sclerosis pill roughly halved the number of disease relapses in two key late-stage…
Roche Expects Blockbuster Cancer Pill Launch by Year End
Roche Holding AG expects to launch the breast cancer pill that may become one of its biggest sellers…
UBS Sees $4 Billion Capital Impact From Swiss Executive Order
UBS Group AG estimated that the now-decided element of new Swiss banking rules will reduce company-wide CET1 capital…
Barclays, Lloyds, UBS Among Banks Picked by UK FCA for AI Tests
Barclays Plc, Lloyds Banking Group Plc and UBS Group AG are among the latest group of lenders in…
Vitol Reorganizes London Derivatives Team After Early Iran War Losses
Vitol Group is reorganizing its derivatives team in London, just weeks after the energy trading giant incurred significant…
Roche Falls as Side Effects Data for Obesity Drug Raises Concern
Shares of Roche Holding AG fell after a poster highlighted side effects in an early-stage study of the…
Roche’s US Biotech Unit Pulls Diversity Targets From Website
Roche Holding AG’s US unit removed diversity and inclusion targets from its website, the latest in a series…
Roche (ROG) Raises Annual Profit Forecast as New Drugs Buoy Sales
Roche Holding AG raised its 2024 profit forecast as new drugs like Vabysmo for eye disease drove revenue…